On Jun. 3, 2021, Innovation Pharma announced that it had achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Innovation Pharmaceuticals developed Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.

Complete trial enrollment comprised 120 dosed patients recruited across multiple sites.